Literature DB >> 25875558

Coexpression of COX-2 and iNOS in Angiogenesis of Superficial Esophageal Squamous Cell Carcinoma.

Youichi Kumagai1, Jun Sobajima, Morihiro Higashi, Toru Ishiguro, Minoru Fukuchi, Keiichiro Ishibashi, Erito Mochiki, Koji Yakabi, Tatsuyuki Kawano, Jun-ichi Tamaru, Hideyuki Ishida.   

Abstract

Using immunohistochemical staining, the present study was conducted to examine whether cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) affect angiogenesis in early-stage esophageal squamous cell carcinoma (ESCC). We also analyzed the correlation between these two factors. Cyclooxygenase 2, iNOS, and angiogenesis in early-stage ESCC are unclear. Using 10 samples of normal squamous epithelium, 7 samples of low-grade intraepithelial neoplasia (LGIN), and 45 samples of superficial esophageal cancer, we observed the expression of COX-2 and iNOS. We then investigated the COX-2 and iNOS immunoreactivity scores and the correlation between COX-2 or iNOS scores and microvessel density (MVD) using CD34 or CD105. The intensity of COX-2 or iNOS expression differed significantly according to histological type (P < 0.001). The scores of COX-2 and iNOS were lowest for normal squamous epithelium, followed in ascending order by LGIN, carcinoma in situ and tumor invading the lamina propria mucosae (M1-M2 cancer); and tumor invading the muscularis mucosa (M3) or deeper cancer. The differences were significant (P < 0.001). Cancers classified M1-M2 (P < 0.01 and P < 0.05, respectively); M3; or deeper cancer (P < 0.01) had significantly higher COX-2 and iNOS scores than normal squamous epithelium. There was a significant correlation between COX-2 and iNOS scores (P < 0.001, rs = 0.51). Correlations between COX-2 score and CD34-positive MVD or CD105-positive MVD were significant (rs = 0.53, P < 0.001; rs = 0.62, P < 0.001, respectively). Inducible nitric oxide synthase score was also significantly correlated with CD34 MVD and CD105 MVD (rs = 0.45, P < 0.001; rs = 0.60, P < 0.001, respectively). Chemoprevention of COX-2 or iNOS activity may blunt the development of ESCC from precancerous lesions.

Entities:  

Keywords:  Angiogenesis; CD105; CD34; COX-2; Esophageal cancer; iNOS

Mesh:

Substances:

Year:  2015        PMID: 25875558      PMCID: PMC4400947          DOI: 10.9738/INTSURG-D-14-00234.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  38 in total

1.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells.

Authors:  Guido Eibl; Dennis Bruemmer; Yuji Okada; John P Duffy; Ronald E Law; Howard A Reber; Oscar J Hines
Journal:  Biochem Biophys Res Commun       Date:  2003-07-11       Impact factor: 3.575

Review 2.  The L-arginine-nitric oxide pathway.

Authors:  S Moncada; A Higgs
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

3.  Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain.

Authors:  J Garthwaite; S L Charles; R Chess-Williams
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

4.  Effects of thiols, sugars, and proteins on nitric oxide activation of guanylate cyclase.

Authors:  J M Braughler; C K Mittal; F Murad
Journal:  J Biol Chem       Date:  1979-12-25       Impact factor: 5.157

Review 5.  Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research.

Authors:  Youichi Kumagai; Masakazu Toi; Haruhiro Inoue
Journal:  Lancet Oncol       Date:  2002-10       Impact factor: 41.316

6.  Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.

Authors:  A Marrogi; H I Pass; M Khan; L J Metheny-Barlow; C C Harris; B I Gerwin
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

7.  Protein S-nitrosylation: a physiological signal for neuronal nitric oxide.

Authors:  S R Jaffrey; H Erdjument-Bromage; C D Ferris; P Tempst; S H Snyder
Journal:  Nat Cell Biol       Date:  2001-02       Impact factor: 28.824

8.  Magnifying endoscopy, stereoscopic microscopy, and the microvascular architecture of superficial esophageal carcinoma.

Authors:  Y Kumagai; H Inoue; K Nagai; T Kawano; T Iwai
Journal:  Endoscopy       Date:  2002-05       Impact factor: 10.093

Review 9.  The structure of mammalian cyclooxygenases.

Authors:  R Michael Garavito; Anne M Mulichak
Journal:  Annu Rev Biophys Biomol Struct       Date:  2003-02-05

10.  Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells.

Authors:  Lei-Chin Chen; Ben-Kuen Chen; Jia-Ming Chang; Wen-Chang Chang
Journal:  Biochim Biophys Acta       Date:  2004-07-05
View more
  5 in total

1.  CCR7 enhances the angiogenic capacity of esophageal squamous carcinoma cells in vitro via activation of the NF-κB/VEGF signaling pathway.

Authors:  Qing-Yong Cai; Gui-You Liang; Yi-Feng Zheng; Qun-You Tan; Ru-Wen Wang; Kun Li
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Chondromodulin-1 and vascular endothelial growth factor-A expression in esophageal squamous cell carcinoma: accelerator and brake theory for angiogenesis at the early stage of cancer progression.

Authors:  Youichi Kumagai; Tetsuhiko Tachikawa; Morihiro Higashi; Jun Sobajima; Akemi Takahashi; Kunihiko Amano; Kei-Ichiro Ishibashi; Erito Mochiki; Koji Yakabi; Jun-Ichi Tamaru; Hideyuki Ishida
Journal:  Esophagus       Date:  2019-10-08       Impact factor: 4.230

3.  Cyclooxygenase-2, a Potential Therapeutic Target, Is Regulated by miR-101 in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Shao; Peng Li; Sheng-tao Zhu; Ji-ping Yue; Xiao-jun Ji; Zhen He; Dan Ma; Li Wang; Yong-jun Wang; Ye Zong; Yong-dong Wu; Shu-tian Zhang
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

4.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22

5.  The Blood Oxygenation T2* Values of Resectable Esophageal Squamous Cell Carcinomas as Measured by 3T Magnetic Resonance Imaging: Association with Tumor Stage.

Authors:  Yu-Lian Tang; Xiao-Ming Zhang; Zhi-Gang Yang; Yu-Cheng Huang; Tian-Wu Chen; Yan-Li Chen; Fan Chen; Nan-Lin Zeng; Rui Li; Jiani Hu
Journal:  Korean J Radiol       Date:  2017-05-19       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.